Peroxisome proliferator-activated receptorγ 배위자의 간암 세포에 대한 항암 효과
Peroxisome proliferator-activated receptorγ ligands exert antineoplastic effects in hepatocellular carcinoma cells
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: Thiazolidinediones, which are synthetic insulin sensitizers, are known activators of peroxisome proliferator-activated receptor gamma (PPARγ). PPARγ ligands, including endogenous 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2), are thought to elicit antineoplastic effects in various cancer cells. In this study, the antineoplastic effects of PPARγ ligands against hepatocellular carcinoma (HCC) cells were investigated. Methods: HepG2, Hep3B, and PLC/PRF5 cells were cultured with troglitazone (TGZ), pioglitazone (PGZ), rosiglitazone (RGZ), or 15d-PGJ2 at concentrations of 20-100 μM.. Cell viability, cell cycle arrest, apoptosis, and caspase activity were measured using the MTT assay, flow cytometry, enzyme-linked immunosorbent assay (ELISA), and colorimetric assays, respectively. The effects of various caspase inhibitors were also measured using a cell death detection ELISA. Results: All three cell lines expressed the PPARγ gene. TGZ and 15d-PGJ2 strongly inhibited growth in HepG2, Hep3B, and PLC/PRF5 cells. In contrast, PGZ and RGZ showed a much weaker effect in all cell lines. In terms of cell cycle arrest and apoptosis, TGZ induced G0/G1 arrest in HepG2 cells and increased the apoptotic fraction in Hep3B and PLC/PRF5 cells. In contrast, 15d-PGJ2 induced apoptosis only in HepG2 and Hep3B cells. TGZ and 15d-PGJ2 increased caspase-3 activity significantly and increased caspase-9 activity slightly. TGZ- and 15d-PGJ2-induced apoptoses were inhibited by a pancaspase inhibitor (Z-VAD-FMK) and a caspase-3 specific inhibitor (Z-DEVD-FMK) in a dose- dependent manner. Conclusions: TGZ and 15d-PGJ2 elicit antineoplastic effects in various HCC cells via caspase-dependent apoptotic induction. Their differential effects on similar cell types suggest that another antineoplastic mechanism, most likely a PPARγ-independent pathway, is involved. (Korean J Med 75:288-299, 2008)
Abstract
Background/Aims: Thiazolidinediones, which are synthetic insulin sensitizers, are known activators of peroxisome proliferator-activated receptor gamma (PPARγ). PPARγ ligands, including endogenous 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2), are thought to elicit antineoplastic effects in various cancer cells. In this study, the antineoplastic effects of PPARγ ligands against hepatocellular carcinoma (HCC) cells were investigated. Methods: HepG2, Hep3B, and PLC/PRF5 cells were cultured with troglitazone (TGZ), pioglitazone (PGZ), rosiglitazone (RGZ), or 15d-PGJ2 at concentrations of 20-100 μM.. Cell viability, cell cycle arrest, apoptosis, and caspase activity were measured using the MTT assay, flow cytometry, enzyme-linked immunosorbent assay (ELISA), and colorimetric assays, respectively. The effects of various caspase inhibitors were also measured using a cell death detection ELISA. Results: All three cell lines expressed the PPARγ gene. TGZ and 15d-PGJ2 strongly inhibited growth in HepG2, Hep3B, and PLC/PRF5 cells. In contrast, PGZ and RGZ showed a much weaker effect in all cell lines. In terms of cell cycle arrest and apoptosis, TGZ induced G0/G1 arrest in HepG2 cells and increased the apoptotic fraction in Hep3B and PLC/PRF5 cells. In contrast, 15d-PGJ2 induced apoptosis only in HepG2 and Hep3B cells. TGZ and 15d-PGJ2 increased caspase-3 activity significantly and increased caspase-9 activity slightly. TGZ- and 15d-PGJ2-induced apoptoses were inhibited by a pancaspase inhibitor (Z-VAD-FMK) and a caspase-3 specific inhibitor (Z-DEVD-FMK) in a dose- dependent manner. Conclusions: TGZ and 15d-PGJ2 elicit antineoplastic effects in various HCC cells via caspase-dependent apoptotic induction. Their differential effects on similar cell types suggest that another antineoplastic mechanism, most likely a PPARγ-independent pathway, is involved. (Korean J Med 75:288-299, 2008)
참고문헌 (27)
- "Korea National Statistical Office. The cause of the death"[URL]
- El-Serag HB, "Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States", Hepatology, 33, pp.62~65 (2001)
- Grommes C, "Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists", Lancet Oncol, 5, pp.419~429 (2004)
- Tontonoz P, "Stimulation of adipogenesis in fibroblasts by PPARγ, a lipid-activated transcription factor", Cell, 79, pp.1147~1156 (1994)
- Frohlich E, "Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture", Endocr Relat Cancer, 12, pp.291~303 (2005)
- Kubota T, "Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo", Cancer Res, 58, pp.3344~3352 (1998)
- Sarraf P, "Differentiation and reversal of malignant changes in colon cancer through PPARγ", Nat Med, 4, pp.1046~1052 (1998)
- Han S, "Peroxisome proliferator-activated receptor ¦: a novel target for cancer therapeutics?", Anticancer Drugs, 18, pp.237~244 (2007)
- Koga H, "Involvement of p21 (WAF1", Cip1), p27 (Kip1), and p18 (INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines, 2001, pp.33, 1087~1097
- McIntyre TM, "Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist", Proc Natl Acad Sci U S A, 100, pp.131~136 (2003)
- Schopfer FJ, "Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand", Proc Natl Acad Sci U S A, 102, pp.2340~2345 (2005)
- Clay CE, "Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells", Carcinogenesis, 20, pp.1905~1911 (1999)
- Shimada T, "Characteristics of the peroxisome proliferator activated receptor gamma (PPARgamma) ligand induced apoptosis in colon cancer cells", Gut, 50, pp.658~664 (2002)
- Kojima K, "Effect of PPARgamma ligands on the viability of gastric epithelial cells", Aliment Pharmacol Ther, 16, pp.67~73 (2002)
- Ray DM, "Human multiple myeloma cells express peroxisome proliferator-activated receptor gamma and undergo apoptosis upon exposure to PPARgamma ligands", Clin Immunol, 113, pp.203~213 (2004)
- Kim JR, "Natural history and survival rate of chronic liver diseases in Korea: 20 years prospective analysis", Korean J Med, 46, pp.168~180 (1994)
- Nolte W, "Glucose metabolism and liver cirrhosis", Exp Clin Endocrinol Diabetes, 103, pp.63~74 (1995)
- Yoshizawa K, "Peroxisome proliferator-activated receptor γ ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines", Cancer, 95, pp.2243~2251 (2002)
- Toyoda M, "A ligand for peroxisome proliferator activated receptor γ inhibits cell growth and induces apoptosis in human liver cancer cells", Gut, 50, pp.563~567 (2002)
- Motomura W, "Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells", Int J Cancer, 108, pp.41~46 (2004)
- Weng JR, "Beyond peroxisome proliferator-activated receptor γ signaling: the multi-facets of the antitumor effect of thiazolidinediones", Endocr Relat Cancer, 13, pp.401~413 (2006)
- Bae MA, "Troglitazone but not rosiglitazone induces G1 cell cycle arrest and apoptosis in human and rat hepatoma cell lines", Toxicol Lett, 139, pp.67~75 (2003)
- Fulzele SV, "15-Deoxy-Delta12,14-prostaglandin J2 enhances docetaxel anti-tumor activity against A549 and H460 non-small-cell lung cancer cell lines and xenograft tumors", Anticancer Drugs, 18, pp.65~78 (2007)
- Shiau CW, "Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL", Bcl-2 functions independently of PPARgamma, 2005, pp.65, 1561~1569
- Rumi MA, "Peroxisome proliferator-activated receptor γ ligandinduced growth inhibition of human hepatocellular carcinoma", Br J Cancer, 84, pp.1640~1647 (2001)
- Nakata S, "15-Deoxy-Delta12,14-prostaglandin J(2) induces death receptor 5 expression through mRNA stabilization independently of PPARγ and potentiates TRAIL-induced apoptosis", Mol Cancer Ther, 5, pp.1827~1835 (2006)
- Ray DM, "The peroxisome proliferatoractivated receptor gamma (PPARgamma) ligands 15-deoxy- Delta12,14 -prostaglandin J2 and ciglitazone induce human B lymphocyte and B cell lymphoma apoptosis by PPARgammaindependent mechanisms", J Immunol, 177, pp.5068~5076 (2006)